MiNK Therapeutics, Inc. (INKT) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $52.00; Additional Paid in Capital, Common StockUSD $149.22M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-699.89K; Retained Earnings (Accumulated Deficit)USD $-162.55M.
- 2026-03-31: Common Stock, Value, IssuedUSD $51.00; Additional Paid in Capital, Common StockUSD $147.43M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-697.43K; Retained Earnings (Accumulated Deficit)USD $-159.42M.
- 2025-12-31: Common Stock, Value, IssuedUSD $48.00; Additional Paid in Capital, Common StockUSD $143.17M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-718.92K; Retained Earnings (Accumulated Deficit)USD $-156.68M.
- 2025-09-30: Common Stock, Value, IssuedUSD $46.00; Additional Paid in Capital, Common StockUSD $141.25M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-692.11K; Retained Earnings (Accumulated Deficit)USD $-154.07M.
MiNK Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Treasury Stock, Retired, Cost Method, Amount USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $52.00 | $149.22M | $-699.89K | $-162.55M | $-14.03M | (m) | (m) |
| 2026-03-31 | $51.00 | $147.43M | $-697.43K | $-159.42M | $-12.69M | (m) | 3 month · $630.38K |
| 2025-12-31 | $48.00 | $143.17M | $-718.92K | $-156.68M | $-14.23M | (m) | 12 month · $13.96K |
| 2025-09-30 | $46.00 | $141.25M | $-692.11K | $-154.07M | $-13.51M | (m) | (m) |
| 2025-06-30 | $40.00 | $126.72M | $-719.32K | $-151.19M | $-25.19M | (m) | 3 month · $8.08K |
| 2025-03-31 | $40.00 | $125.82M | $-662.44K | $-146.95M | $-21.79M | (m) | 3 month · $5.88K |
| 2024-12-31 | $40.00 | $125.23M | $-631.58K | $-144.18M | $-19.59M | (m) | 12 month · $106.83K |
| 2024-09-30 | $395.00 | $124.84M | $-672.84K | $-141.72M | $-17.55M | (m) | 3 month · $25.50K |
| 2024-06-30 | $394.00 | $123.95M | $-611.38K | $-139.91M | $-16.58M | (m) | 3 month · $25.31K |
| 2024-03-31 | $347.00 | $117.30M | $-385.78K | $-137.21M | $-20.30M | (m) | 3 month · $27.03K |
| 2023-12-31 | $35.00 | $115.77M | $-430.95K | $-133.40M | $-18.06M | 12 month · $477.64K | 12 month · $131.93K |
| 2023-09-30 | $345.00 | $114.67M | $-313.19K | $-127.94M | $-13.58M | (m) | 3 month · $33.11K |
| 2023-06-30 | $345.00 | $113.73M | $-401.81K | $-122.82M | $-9.50M | 3 month · $97.72K | 3 month · $33.35K |
| 2023-03-31 | $343.00 | $112.52M | $-373.80K | $-116.63M | $-4.48M | 3 month · $379.92K | 3 month · $33.33K |
| 2022-12-31 | $339.00 | $110.83M | $-292.47K | $-110.94M | $-401.30K | 12 month · $157.19K | 12 month · $96.01K |
| 2022-09-30 | $338.00 | $110.00M | $-78.28K | $-103.17M | $6.76M | (m) | 3 month · $27.02K |
| 2022-06-30 | $337.00 | $109.23M | $1.30M | $-96.84M | $13.69M | 3 month · $157.19K | 3 month · $3.89K |
| 2022-03-31 | $336.00 | $108.14M | $-102.50K | $-90.72M | $17.31M | (m) | 3 month · $43.73K |
| 2021-12-31 | $335.00 | $107.35M | $-625.27K | $-82.95M | $23.78M | (m) | 12 month · $124.26K |
| 2021-09-30 | $242.00 | $1.46M | $-789.34K | $-77.18M | $-76.51M | (m) | 3 month · $21.60K |
| 2021-06-30 | (m) | (m) | (m) | (m) | $-63.18M | (m) | 3 month · $51.21K |
| 2021-03-31 | (m) | (m) | (m) | (m) | $-57.08M | (m) | 3 month · $19.95K |
| 2020-12-31 | $242.00 | $383.71K | $-1.52M | $-52.74M | $-53.87M | (m) | 12 month · $86.46K |
| 2020-09-30 | (m) | (m) | (m) | (m) | $-51.34M | (m) | 3 month · $10.41K |
| 2020-06-30 | (m) | (m) | (m) | (m) | $-44.50M | (m) | 3 month · $12.63K |
| 2020-03-31 | (m) | (m) | (m) | (m) | $-40.06M | (m) | 3 month · $29.53K |
| 2019-12-31 | (m) | (m) | (m) | (m) | $-36.33M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |